Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Roche reported better than expected first-half operating profit, driven by strong sales of breast cancer and asthma ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Roche (RHHBY) plans direct-to-patient drug sales in the U.S. to avoid the influence from pharmacy benefit managers in product ...

Positive topline results of the LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.